Iruplinalkib Improves PFS Vs Crizotinib in Locally Advanced or Metastatic ALK+ NSCLC

September 10, 2023Kristi RosaTreatment with iruplinalkib significantly improved progression-free survival and produced a higher objective response rate compared with crizotinib in patients with ALK TK

Updated on: October 11,2023

Iruplinalkib Improves PFS Vs Crizotinib in Locally Advanced or Metastatic ALK+ NSCLC

September 10, 2023Kristi RosaTreatment with iruplinalkib significantly improved progression-free survival and produced a higher objective response rate compared with crizotinib in patients with ALK TK

Updated on:October 11,2023

Missing a Rare Cause of Hereditary Cancer

New research fromCedars-Sinai Cancerinvestigators could warrant reconsideration of current screening guidelines to include a poorly recognized cause of Lynch syndrome, the most common caus

Updated on: November 07,2023

Missing a Rare Cause of Hereditary Cancer

New research fromCedars-Sinai Cancerinvestigators could warrant reconsideration of current screening guidelines to include a poorly recognized cause of Lynch syndrome, the most common caus

Updated on:November 07,2023

Study identifies genetic cause for some brain tumors

Study identifies genetic cause for some brain tumorsby Olivia Dimmer,Northwestern UniversityMultiplex immunofluorescence staining and imaging using the COMET system platform on a human meningiom

Updated on: October 30,2023

Study identifies genetic cause for some brain tumors

Study identifies genetic cause for some brain tumorsby Olivia Dimmer,Northwestern UniversityMultiplex immunofluorescence staining and imaging using the COMET system platform on a human meningiom

Updated on:October 30,2023

Secrets of lung cancer spread found in patients’ blood and biopsies

byCancer Research UK| News7 October 2019Early signs that a patient’s lung cancer may spread and become untreatable can be picked up in samples of their blood and tumour, according to a tri

Updated on: December 19,2023

Secrets of lung cancer spread found in patients’ blood and biopsies

byCancer Research UK| News7 October 2019Early signs that a patient’s lung cancer may spread and become untreatable can be picked up in samples of their blood and tumour, according to a tri

Updated on:December 19,2023

Patient-derived Organoids: Revolutionizing Cancer Research and Treatment

Updated on: November 14,2024

Patient-derived Organoids: Revolutionizing Cancer Research and Treatment

Updated on:November 14,2024

Standard of care chemoradiation for stage III non-small cell lung cancer is superior to two tested alternatives

by NRG OncologyCredit: CC0 Public DomainLung cancer is the leading cause of cancer death in the United States and approximately 75-80 percent of all cases are non-small cell lung cancer (NSCLC). Of th

Updated on: December 22,2023

Standard of care chemoradiation for stage III non-small cell lung cancer is superior to two tested alternatives

by NRG OncologyCredit: CC0 Public DomainLung cancer is the leading cause of cancer death in the United States and approximately 75-80 percent of all cases are non-small cell lung cancer (NSCLC). Of th

Updated on:December 22,2023

What you need to know after a breast cancer diagnosis

by Robin FosterBreast cancer strikes 1 in 8 women in the United States, but being diagnosed with the disease can still make you feel alone.To cope with such devastating news, breast cancer surgeons fr

Updated on: October 24,2024

What you need to know after a breast cancer diagnosis

by Robin FosterBreast cancer strikes 1 in 8 women in the United States, but being diagnosed with the disease can still make you feel alone.To cope with such devastating news, breast cancer surgeons fr

Updated on:October 24,2024

MK256 is a novel CDK8 inhibitor with potent antitumor activity in AML through downregulation of the STAT pathway

by Impact Journals LLCEvaluation of the toxicity of MK256 in vivo. Credit:Oncotarget(2022). DOI: 10.18632/oncotarget.28305A new research paper titled "MK256 is a novel CDK8 inhibitor

Updated on: December 17,2023

MK256 is a novel CDK8 inhibitor with potent antitumor activity in AML through downregulation of the STAT pathway

by Impact Journals LLCEvaluation of the toxicity of MK256 in vivo. Credit:Oncotarget(2022). DOI: 10.18632/oncotarget.28305A new research paper titled "MK256 is a novel CDK8 inhibitor

Updated on:December 17,2023

What Is B-Cell Lymphoma?

What Is B-Cell Lymphoma?ByCorey WhelanPublished on February 23, 2022Medically reviewed byGagandeep Brar, MDB-cell lymphoma is a type ofnon-Hodgkin's lymphoma (NHL). N

Updated on: January 28,2024

What Is B-Cell Lymphoma?

What Is B-Cell Lymphoma?ByCorey WhelanPublished on February 23, 2022Medically reviewed byGagandeep Brar, MDB-cell lymphoma is a type ofnon-Hodgkin's lymphoma (NHL). N

Updated on:January 28,2024

Fixed-Duration Mosunetuzumab Elicits Durable Responses in R/R Follicular Lymphoma

June 27, 2023Kristi RosaFixed-duration treatment with single-agent mosunetuzumab resulted in a high complete response rate by end of treatment in patients with relapsed or refractory follicular lympho

Updated on: October 15,2023

Fixed-Duration Mosunetuzumab Elicits Durable Responses in R/R Follicular Lymphoma

June 27, 2023Kristi RosaFixed-duration treatment with single-agent mosunetuzumab resulted in a high complete response rate by end of treatment in patients with relapsed or refractory follicular lympho

Updated on:October 15,2023

Survival rates high for children, teens with melanoma

by Lori SolomonSurvival rates for children and adolescents with melanomas are high, according to a study published online Dec. 9 in theJournal of the American Academy of Dermatology.Mary-Ann El

Updated on: December 21,2023

Survival rates high for children, teens with melanoma

by Lori SolomonSurvival rates for children and adolescents with melanomas are high, according to a study published online Dec. 9 in theJournal of the American Academy of Dermatology.Mary-Ann El

Updated on:December 21,2023

After Pembrolizumab/Lenvatinab Provides Clinical Benefit in Previously Treated Endometrial Cancer

October 23, 2023Dylann Cohn-EmeryContinued treatment with lenvatinib monotherapy after the completeion of combination therapy with pembrolizumab and lenvatinib resulted in sustained clinical benefit v

Updated on: October 24,2023

After Pembrolizumab/Lenvatinab Provides Clinical Benefit in Previously Treated Endometrial Cancer

October 23, 2023Dylann Cohn-EmeryContinued treatment with lenvatinib monotherapy after the completeion of combination therapy with pembrolizumab and lenvatinib resulted in sustained clinical benefit v

Updated on:October 24,2023